Twist Bioscience revenue and financials
$205.00Change from previous close: +8.66%Absolute change: +$16.33
In the fiscal year ended September 2025, Twist Bioscience reported revenue of $376.57M (+20.32% year over year). The net loss was $77.67M.
Fiscal year ending in September. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +20.32%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- -20.6%
- FY to Sep 2024: -66.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 | FY to Sep 2021 | FY to Sep 2020 | FY to Sep 2019 | FY to Sep 2017 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 642 | 614 | 776 | 961 | 702 | 399 | 187 | — |
| Current assets | 333 | 347 | 424 | 596 | 546 | 335 | 160 | — |
| Cash and equivalents | 183 | 226 | 286 | 379 | 466 | 93.7 | 46.7 | 31.2 |
| Short-term investments | 49.4 | 50.1 | 49.9 | 126 | 12.0 | — | — | — |
| Receivables | 57.0 | 34.9 | 44.1 | 40.3 | 28.5 | — | — | — |
| Inventory | 28.3 | 24.1 | 32.1 | 39.3 | 31.8 | — | — | — |
| Net property, plant and equipment | 152 | 161 | 203 | 214 | 106 | — | — | — |
| Goodwill | 82.2 | 85.8 | 85.8 | 85.8 | 22.4 | 1.1 | 1.1 | — |
| Other intangible assets | 13.4 | 14.5 | 54.5 | 59.7 | 18.3 | — | — | — |
| Long-term investments | 54.3 | 1.5 | — | — | — | — | — | — |
| Current liabilities | 91.4 | 71.0 | 73.3 | 90.7 | 63.1 | 36.0 | 30.4 | — |
| Accounts payable | 11.1 | 1.6 | 14.1 | 20.1 | 14.9 | — | — | — |
| Long-term debt | 15.0 | — | — | — | — | 4.2 | 7.5 | — |
| Total debt | 75.6 | 85.0 | 94.1 | 94.9 | — | — | — | — |
| Total liabilities | 169 | 142 | 153 | 172 | 121 | 62.6 | 34.9 | — |
| Total equity (incl. minority) | 473 | 473 | 623 | 789 | 581 | — | — | — |
| Retained earnings | -1,320 | -1,242 | -1,033 | -828 | -611 | — | — | — |